2021-09-006 - PLP-3 - Novel antimicrobial peptide for the treatment of multidrug resistant bacteria
Contacts
AO
CH
Acronim & Gínjol codes
PLP-3
2021-09-006
Main technology offer
Novel antimicrobial peptides active against a broad panel of Gram-negative pathogens. Keeps lower haemolytic and cytotoxic activity in front of human cells.
Ownership
Barcelona, Spain
2005
Institut de Recerca Biomèdica (IRB Barcelona)
Barcelona, Spain
2010
Institut de Salut Global de Barcelona (ISGlobal)
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Deaths linked to Carbapenem-resistant gram-negative bacteria have risen by nearly 150%, from 50,900 cases in 1990 to 127,000 cases in 2021. A new antibiotic able to treat these difficult infections will reduce drastically this death ratio.
Market Data
The rise in infections due to antimicrobial-resistant bacteria is a huge public health problem. Clinicians every day have fewer tools to treat some types of infections and routine clinical procedures such as surgeries and joint replacements are becoming riskier. Bacteria have mutated very fast due to the misuse and overuse of antibiotics and, dramatically, the development of new antibiotic classes is very slow. Here, we present a new bicyclic peptide with strong antibiotic properties, especially for the most dangerous Gram-negative pathogens such as A.baumannii and P.aeruginosa, two of the most deadly species listed by the WHO.
0
0
0
Our business model is based on to develop the technology until the preclinical phase (TRL4-5) and to out-license the asset to a pharma or a biomedical company with antibiotics in their pipeline.
Antibiotics that can act against antimicrobial-resistant bacteria
Antibiotics market, specifically against gram-negative pathogenes such as A.baumannii and P.aeruginosa
Funding
We have calculated we will need 1M€ to bring our product to the preclinical phase
Partnership with industry Collaborators
2025-2026 in vivo proof of concept 2027: license agreement negotiation
Technology Status
More active than other antimicrobial peptides under development Interesting therapeutic window, low toxicity in HeLa cells, and low haemolysis Bactericidal and very rapid killer Similar and more stable than murepavadin which is in the clinical phases for cystic fibrosis caused by P. aeruginosa
Long and costly drug discovery process High ratio of failure Lack of interest by big pharma companies Absence of incentives by governments and policymakers to attract investment
PCT application has entered in national phases: USA, Europe and China. Excellent perspectives to be granted based on positive evaluations by EPO
May 22: very positive EESR report. PCT application in national phases in December 2024: China, Europe and the USA. We have signed a service agreement with the NIAID (National Institutes of Allergy and Infectious Diseases) in 2022 to use their preclinical services for five years of duration. We have perfomed MTD studies (via intravenous) with Pharmacology Discovery Services and currenly carrying out PK/PD studies with the company AnaPath (via intraperitoneal).
Know-how on antibiotic development
Additional information
PLP-3 is a promising set of novel antimicrobial peptides active against a broad panel of Gram-negative pathogens (including 45 critical multidrug resistant strains), while keeping lower haemolytic and cytotoxic activity in front of human cells.